Stockholm, Sweden, January 30, 2025; Inify Laboratories AB (publ.) has been
notified that the following transactions have been completed by a primary
insider in Inify; Olof Sandén, board member and primary insider in Inify, has
acquired 16,840 shares in Inify at an average price of SEK 4.36 per share during
January 27th - 29th. After the transactions, Sandén controls 116,840 shares.

This information is subject to the disclosure requirements pursuant to the EU
Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the
Norwegian Securities Trading Act.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com.

###

About Inify Laboratories

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI-
supported workflow to optimize quality and response times, initially within
prostate.The concept is scalable and can be extended to other diagnoses.
The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist. The report is assisted by our
own AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system.
The company, based in Sweden, became independent in 2022 through a spin-off
fromContextVision (https://www.contextvision.com/), with 40 years of experience
within digital imaging for medical applications. It is listed onEuronext Growth
Oslo under the ticker
INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).


